EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Autoantibodies against angiotensin‐converting enzyme 2 (ACE2) after COVID‐19 infection or vaccination

James Yiu Hung Tsoi iD, Jianpiao Cai, Jianwen Situ, Winston Jim Lam, Estie Hon Kiu Shun iD, Joy Ka Yi Leung, Lin Lei Chen, Brian Pui Chun Chan, Man Lung Yeung, Xin Li iD, Kwok Hung Chan, Joshua Sung Chih Wong und 4 weitere

Journal of Medical Virology · 2023-12 · 95 (12)

DOI: 10.1002/jmv.29313 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 15.12.2023. Verfasst von James Yiu Hung Tsoi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China. Hauptthemen laut MEDLINE: COVID-19, Myocarditis. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Li Ka Shing Faculty of Medicine, University of Hong Kong, National Key Research and Development Program of China, Research Grants Council, University Grants Committee.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoantibodies against angiotensin‐converting enzyme 2 (ACE2) are frequently reported in patients during coronavirus disease 2019 (COVID‐19) with evidence for a pathogenic role in severe infection. However, little is known of the prevalence or clinical significance of ACE2 autoantibodies in late convalescence or following COVID‐19 vaccination. In this study, we measured ACE2 autoantibodies in a cohort of 182 COVID‐19 convalescent patients, 186 COVID‐19 vaccine recipients, and 43 adolescents with post‐mRNA vaccine myopericarditis using two ACE2 enzymatic immunoassays (EIAs). ACE2 IgM autoantibody EIA median optical densities (ODs) were lower in convalescent patients than pre‐COVID‐19 control samples with only 2/182 (1.1%) convalescents testing positive. Similarly, only 3/182 (1.6%) convalescent patients tested positive for ACE2 IgG, but patients with history of moderate‐severe COVID‐19 tended to have significantly higher median ODs than controls and mild COVID‐19 patients. In contrast, ACE2 IgG antibodies were detected in 10/186 (5.4%) COVID‐19 vaccine recipients after two doses of vaccination. Median ACE2 IgG EIA ODs of vaccine recipients were higher than controls irrespective of the vaccine platform used (inactivated or mRNA). ACE2 IgG ODs were not correlated with surrogate neutralizing antibody levels in vaccine recipients. ACE2 IgG levels peaked at day 56 post‐first dose and declined within 12 months to baseline levels in vaccine recipients. Presence of ACE2 antibodies was not associated with adverse events following immunization including myopericarditis. One convalescent patient with ACE2 IgG developed Guillain−Barre syndrome, but causality was not established. ACE2 autoantibodies are observed in COVID‐19 vaccine recipients and convalescent patients, but are likely innocuous.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19MyocarditisAdolescentHumansAutoantibodiesCOVID-19 VaccinesAngiotensin-Converting Enzyme 2VaccinationAntibodies, NeutralizingImmunoglobulin GAntibodies, Viral

Stichwörter der Autor:innen

ACE2COVID-19COVID-19 vaccineSARS-CoV-2autoantibodyenzymatic immunoassay

Substanzen

AutoantibodiesCOVID-19 VaccinesAngiotensin-Converting Enzyme 2Antibodies, NeutralizingImmunoglobulin GAntibodies, Viral

Autor:innen und Institutionen

  • Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong, China.
  • Centre for Virology, Vaccinology and Therapeutics, The University of Hong Kong, Hong Kong, China.
  • Department of Paediatrics and Adolescent Medicine, Princess Margaret Hospital, Hong Kong, China.
  • State Key Laboratory of Emerging Infectious Diseases, The University of Hong Kong, Hong Kong, China.
  • Carol Yu Centre for Infection, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.

ORCID-Profile: James Yiu Hung Tsoi, Estie Hon Kiu Shun, Xin Li, Kelvin Kai Wang To, Siddharth Sridhar

Förderung

  • Li Ka Shing Faculty of Medicine, University of Hong Kong
  • National Key Research and Development Program of China
  • Research Grants Council, University Grants Committee
  • Health and Medical Research Fund
  • HKUMed Research Fellowship Scheme for Clinical Academics 2022-23
  • Collaborative Research Fund
  • Theme-Based Research Scheme
  • National Key Research and Development Program

Zitieren

APA

Tsoi, J. Y. H., Cai, J., Situ, J., Lam, W. J., Shun, E. H. K., Leung, J. K. Y., Chen, L. L., Chan, B. P. C., Yeung, M. L., Li, X., Chan, K. H., Wong, J. S. C., Kwan, M. Y. W., To, K. K. W., Yuen, K. Y., & Sridhar, S. (2023). Autoantibodies against angiotensin‐converting enzyme 2 (ACE2) after COVID‐19 infection or vaccination. Journal of Medical Virology, 95(12). https://doi.org/10.1002/jmv.29313

Vancouver

Tsoi JYH, Cai J, Situ J, Lam WJ, Shun EHK, Leung JKY, et al. Autoantibodies against angiotensin‐converting enzyme 2 (ACE2) after COVID‐19 infection or vaccination. Journal of Medical Virology. 2023;95(12). doi:10.1002/jmv.29313

BibTeX
@article{Tsoi2023,
  author = {Tsoi, James Yiu Hung and Cai, Jianpiao and Situ, Jianwen and Lam, Winston Jim and Shun, Estie Hon Kiu and Leung, Joy Ka Yi and Chen, Lin Lei and Chan, Brian Pui Chun and Yeung, Man Lung and Li, Xin and Chan, Kwok Hung and Wong, Joshua Sung Chih and Kwan, Mike Yat Wah and To, Kelvin Kai Wang and Yuen, Kwok Yung and Sridhar, Siddharth},
  title = {Autoantibodies against angiotensin‐converting enzyme 2 (ACE2) after COVID‐19 infection or vaccination},
  journal = {Journal of Medical Virology},
  year = {2023},
  volume = {95},
  number = {12},
  doi = {10.1002/jmv.29313}
}
Kostenlos starten →